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Abstract
Dopamine promotes the execution of positively reinforced actions, but its role for the formation of behaviour when
feedback is unavailable remains open. To study this issue, the performance of treated/untreated patients with Parkinson’s
disease and controls was analysed in an implicit learning task, hypothesising dopamine-dependent adherence to hidden
task rules. Sixteen patients on/off levodopa and fourteen healthy subjects engaged in a Go/NoGo paradigm comprising four
equiprobable stimuli. One of the stimuli was defined as target which was first consistently preceded by one of the three
non-target stimuli (conditioning), whereas this coupling was dissolved thereafter (deconditioning). Two task versions were
presented: in a ‘Go version’, only the target cue required the execution of a button press, whereas non-target stimuli were
not instructive of a response; in a ‘NoGo version’, only the target cue demanded the inhibition of the button press which
was demanded upon any non-target stimulus. Levodopa influenced in which task version errors grew from conditioning to
deconditioning: in unmedicated patients just as controls errors only rose in the NoGo version with an increase of incorrect
responses to target cues. Contrarily, in medicated patients errors went up only in the Go version with an increase of
response omissions to target cues. The error increases during deconditioning can be understood as a perpetuation of
reaction tendencies acquired during conditioning. The levodopa-mediated modulation of this carry-over effect suggests
that dopamine supports habit conditioning under the task demand of response execution, but dampens it when inhibition
is required. However, other than in reinforcement learning, supporting dopaminergic actions referred to the most frequent,
i. e., non-target behaviour. Since this is passive whenever selective actions are executed against an inactive background,
dopaminergic treatment could in according scenarios contribute to passive behaviour in patients with Parkinson’s disease.
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Introduction
Replacement of depleted dopamine (DA) is the central principle
in the treatment of Parkinson’s disease (PD) [1,2] with beneficial
motor, but less predictable non-motor effects. This discrepancy
can be explained by the preponderance of PD-related DA
deficiency in specific brain regions [3]. Over a long period after
disease onset, nigral projections to dorsal parts of the striatum are
worst affected leading to the major motor symptoms [4], while
other dopaminergic networks remain comparably intact [5].
Accordingly, DA replacement for the movement disorder may
overdose brain areas without relevant DA deficit [6–9].
In this context, DA-dependent functions of the mesocortical
system, spanning from the ventral tegmental area to frontal
regions, are of particular interest. This network is strongly involved
in learning processes [10–12] and, in PD patients, has been related
to the development of impulsive-compulsive disorders, understood
as the consequence of enhanced learning from positively
reinforced actions under dopaminergic drugs [13–18].
Little is known about the influence of DA replacement on non-
reinforced learning, but hypotheses may be derived from some
general functions attributed to DA in corticobasal networks. DA has
been proposed to regulate the trade off between stability and
flexibility. Specifically, high striatal levels are thought to support
the flexible adaptation to changing environmental conditions,
whereas high mesocortical concentrations seem to stabilise ongoing
behavioural goals [19–21]. With respect to learning patterns in PD,
this could mean that in treated PD patients excessively driven
mesocortical functions would fixate acquired behaviour, whereas
striatal DA depletion in untreated patients should slow down
gradual learning from changing environmental rules.
To test these assumptions, the performance of PD patients on
versus off levodopa and of healthy controls was analysed in a task,
requiring reactions to seldom target cues intermingled between
frequent non-target stimuli without feedback control. The target
cues were first preceded by one out of several non-target stimuli
(conditioning phase) and then presented in random order
(deconditioning phase), resembling the general structure of Nissen
& Bullemer’s serial reaction time (SRT) task for the assessment of
implicit learning [22]. This SRT aspect was embedded in a Go/
NoGo design, since in reinforcement learning high DA levels
support the learning of rewarded actions, but unfold detrimental
effects when inhibition learning is required [9,13,16,17,23,24].
In order not to miss a similar DA-dependent modulation in
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instructions: first, in a ‘Go version’, target cues were instructive for
the release of a button press, whereas non-target stimuli did not
require any response, and, second, in a ‘NoGo version’ only upon
target cues the button press had to be withheld, while it was
required upon all non-target stimuli.
Under the basic idea that performance declines during
deconditioning could indicate the carry-over of (no longer valid)
rule representations built up during conditioning, reaction times
and error rates were compared between these task phases.
Methods
Participants
Sixteen patients participated in the current study (11 male, 5
female; 64.466.6 years of age; 14.063.7 years of education [mean
6 standard deviation]). They were recruited from the Outpatient
Clinic for Neurological Movement Disorders of the Charite ´
(Campus Benjamin Franklin) and fulfilled the Brain Bank Criteria
for PD. From the patients sent to the Outpatient Clinic, those with
levodopa monotherapy (7726618 mg) were selected to avoid
confounding effects from other antiparkinson drugs, and experi-
ments were conducted before further drug adjustments. Exclusion
criteria were the presence of neurological disease apart from PD,
the intake of drugs with central mechanisms of action besides
levodopa, and less than 24 points in the Mini Mental State
Examination (MMSE) [25]. Further, 14 healthy subjects (8 male, 6
female; 68.464.5 years of age; 15.662.8 years of education), free
from the aforementioned exclusion criteria, took part in the
experiment as controls.
All participants were right-handed, as assessed by Oldfield’s
handedness inventory [26]. Further, the scores for the motor part
of the Unified Parkinson’s Disease Rating Scale (UPDRS, part 3),
the Beck Depression Inventory (BDI) and the Fatigue Severity
Scale (FSS) were determined to delineate putative cognitive,
affective and fatigue-related disorders [27–29]. The data are
summarized in Table 1. All participants gave written informed
consent to the study protocol approved by the Ethics Committee
of the Charite ´. Since we aimed at comparing effects of levodopa
medication, patients engaged in the experiments twice, once under
treatment (on condition) and once after overnight withdrawal (off
condition) with a minimum interval of 4 weeks between both
sessions. The medication state, in which patients first accom-
plished the experiment, was balanced for both task conditions.
Experimental procedure
The participants engaged in two task conditions, demanding
selective reactions to visually presented target and non-target signals.
In the Go version of the task, they had to respond to a predefined
target signal by a right-finger button press, whereas responses should
not be given to any of the other signals (non-targets). In contrast to
this, in the NoGo version the right-finger button press had to be
performed upon any non-target signal, whereas only upon the target
signal this response had to be withheld.
In both the Go and NoGo task version four equiprobable visual
stimuli occurred, one of which was the target and three of which
were non-targets. Over blocks of 120 signals (conditioning), the
target signal was consistently preceded by the same non-target
signal (in the following labelled precue). After each conditioning
block, this coupling was dissolved, i. e., the former precue did no
longer precede the target cue for a block of 40 signals
(deconditioning). Every 160 signals (conditioning plus decondi-
tioning) a new conditioning phase with another precue (but
constant target) began. Five alternating conditioning/decondition-
ing phases were run, overall containing 800 presentations (cf.
Fig. 1).
Importantly, participants should not become aware of the
alternating structure of the task. To this end, every 200 trials,
pauses of one minute were held. In so doing, conditioning and
deconditioning phases never appeared at the same point in time
with respect to the breaks to avoid conscious perception of the task
rules and trend effects from decaying vigilance or attention.
Subjects sat at 1.5 m from a 179 computer screen with the index
finger comfortably positioned over a push-button on the right-
hand armrest. All stimuli popped up within a constantly present
666 cm frame in the middle of the screen. The presentation time
of target and non-target signals (including precues) was set to
175 ms, the interstimulus interval to 1000 ms.
Statistical Analysis
Demographic data and clinical score values were compared
between control subjects and patients (on versus off levodopa) with
unpaired and,pairedt-tests,respectively.Fortheanalysisofresponse
latencies (accepted within a range of 150 to 900 ms after Go stimuli)
andaccuracyoftaskperformance,two-wayANOVAswererunwith
respect to reaction times and error rates if the data met criteria for
parametrictesting due to Kolmogorov-Smirnowand Levenetesting.
Group was included as three-level test factor (control subjects/
patients off levodopa/patients on levodopa) and Learning Phase as a
test factor with four levels, specified as equally long segments of
performance throughout each block of conditioning and subsequent
deconditioning (performance over stimulus 1–40/41–80/81–120/
121–160,the lattersegmentbeing the deconditioningphase). Incase
of sphericity violations, Huynh-Feldt corrections were performed.
Post-hoc comparisons were run as t-tests.
The rationale behind treating results from the same PD patients
on versus off levodopa as stemming from different groups was that
we aimed at the broadest possible analysis of medication-
dependent modulation of normal task performance, together with
a comprehensive assessment of putative interactions of the test
factors. Importantly, this statistical approach is particularly
conservative, since it minimises the risk of erroneously assuming
differences between treated and untreated PD patients. The
reason for this is that the statistical assumption of data variance is
larger for cohorts with distinct than with identical subject, so that
the treatment of within-subject as between-subject information
overestimates data analogousness.
Only in the deconditioning phase of the Go version, errors to
target cues in patients on levodopa were not normally distributed.
Accordingly, we abstained from running an ANOVA in this case,
and compared target responses during conditioning and decondi-
tioning with the non-parametric Wilcoxon-test.
Table 1. Clinical data.
UPDRS BDI MMSE FSS
Controls 0.961.2 5.263.2 29.160.9 28.4612.5
PD-on 19.5627.8 6.265.6 28.161.8 28.6615.5
PD-off 29.5629.7 6.963.7 28.461.9 28.5614.3
Patients differed between on and off levodopa states and from controls with
respect to the scores in the Unified Parkinson’s Disease Rating Scale (UPDRS).
Normal values without significant differences between groups were obtained
in the Beck Depression Inventory (BDI), the Mini Mental State Examination
(MMSE) and the Fatigue Severity Scale (FSS). All data are provided as mean
values 6 standard deviation.
doi:10.1371/journal.pone.0027695.t001
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With respect to demographic and non-motor scores (age, years
of education, BDI, FSS, MMSE) no differences were obtained
between patients and control subjects or between patients on and
off levodopa (p..05). Only in regard to the motor UPDRS, we
revealed an expected statistical distinction both between patients
on and off levodopa as well as between patients in both medication
states and controls (p,.01).
In the debriefing procedure held as a standardized oral
interrogation after the experiment none of the participants could
report on any coupling of signals or on the alternation of task
sequences, which suggests that the task structure remained hidden.
Reaction Time (RT)
In both the Go and NoGo condition of the task, ANOVAs
proved Learning Phase to be a main factor for RT [Go: F(1.9,
73)=12.36, p,.01; Nogo: F(3, 129)=20.38, p,.01]. Post-hoc tests
demonstrated that this effect, concerning target reactions in the
Go condition and non-target reactions in the NoGo condition, was
due to significant increases of response latencies in the last segment
of each block, i. e. during deconditioning as compared to the
conditioning phase (deconditioning versus conditioning block 1 to
3 for Go: p,.05; for NoGo: p,.01). No significant differences were
obtained across the different conditioning blocks. Although on
average controls responded somewhat faster than PD patients on
and off levodopa, Group was not identified as a factor of RT.
Further, no interaction between Learning Phase and Group was found
(cf. Fig. 2). No response had to be excluded based on the criterion
of response latencies between 150 to 900 ms after Go stimuli.
Accuracy
In the NoGo version of the task, the ANOVA of errors to target
stimuli revealed Learning Phase to be a main factor [F(2,
86.2)=20.5, p,.01]. Further, Group interacted with Learning Phase,
demonstrating that errors did not occur uniformly across groups
Figure 1. Task structure. Four neutral and equiprobable symbols were presented in pseudorandomised order, one of which was defined as target
signal.Duringaconditioningphaseof120signalpresentations,thetarget was alwaysprecededbyone ofthethreenon-targetsignals (precue).Overthe
subsequent 40 presentations, this precue-target coupling was dissolved (deconditioning phase). The conditioning-deconditioning sequence
(comprising 160 presentations) was repeated five times with alternating precues. To avoid conscious recognition of the task structure, one-minute
pauses were held every 200 trials. Thus, conditioning and deconditioning phases never appeared at the same point in time with respect to the breaks.
doi:10.1371/journal.pone.0027695.g001
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demonstrated that the interaction Group6Learning Phase was due to
the fact that in control subjects and patients off levodopa
erroneous target reactions increased during deconditioning,
whereas this was not the case in PD patients on levodopa. Thus,
in the NoGo version of the task, only unmedicated patients and
healthy persons tended to respond to target cues during
deconditioning when the suppression of this reaction was actually
demanded (deconditioning versus learning block 1 to 3 for PD
patients off levodopa/control subjects: p,.01/.05; same compar-
isons for PD patients on levodopa: p..05; cf. Fig. 3).
In the Go version of the task, errors to target stimuli were not
normally distributed in patients on levodopa in the deconditioning
phase and, accordingly, an ANOVA was not run in this case.
Instead, comparisons equivalent to those for the NoGo version of
the task were performed. In controls and patients off levodopa t-
tests did not show any differences between errors, neither between
the different conditioning blocks nor between conditioning blocks
and deconditioning. In patients on levodopa, however, errors
increased during deconditioning compared to all conditioning
blocks (Wilcoxon-testing of deconditioning vs. conditioning blocks
1t o3 :p,.05). Between the conditioning blocks no change of
erroneous target responses was identified. Thus, only PD patients
on levodopa tended to omit required target responses in the
deconditioning phase of the Go version of the task. This is
summarised in Fig. 4.
No effects of conditioning or deconditioning were identified by
the ANOVAs for non-target reactions, neither in the Go nor in the
NoGo version of the task. However, it was assumed that the
overall analysis of all non-target reactions could have blurred the
statistical proof of main factors, given that only specific stimulus
sequences were expected to induce erroneous non-target reactions.
Therefore, it was additionally analysed if during deconditioning
the error rate after stimuli following former precues was higher
than the error rates to non-target stimuli which were not preceded
by former precues. This would have indicated that behaviour
relying on the main conditioning rule, namely to provide a target
reaction to stimuli after precues, had been carried over to the
deconditioning phase (in which former precues preceded non-
target stimuli, thus potentially facilitating erroneous target
reactions). Worthwhile noticing, however, respective t-tests did
not reveal any such effect.
Altogether, in the analysis of performance accuracy a
dissociation of erroneous target reactions was found between Go
and NoGo condition with healthy subjects and patients off
levodopa on the one hand and patients on levodopa on the other
hand.
Discussion
This study aimed at analysing effects of central DA supply on
non-reinforced learning. Therefore, PD patients on and off
levodopa as well as healthy subjects engaged in a Go/NoGo task
with alternating conditioning and deconditioning of target cues.
According to assumptions on DA in corticobasal systems, it was
hypothesised that unmedicated PD patients would be impaired in
learning from conditioning, reflecting striatal DA deficiency with
slowed acquisition of environmental rules [20]. Contrarily, we
Figure 2. Reaction times during conditioning and deconditioning. Average reaction times are displayed per group over blocks of 40
presentations, exemplified by the responses to non-target cues in the NoGo task version with the highest number of responses (no difference was
obtained between task versions). Since conditioning-deconditioning sequences comprised 120 presentations during conditioning followed by 40
presentations during deconditioning, block 1 to 3 (labelled C1, C2 and C3) reflect performance during conditioning, whereas block 4 (labelled D)
equates to deconditioning. The error bars indicate the standard error of the mean. Note that reaction times increased significantly during
deconditioning compared to any of the conditioning blocks (indicated by asterisks) over all groups.
doi:10.1371/journal.pone.0027695.g002
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conditioned actions, reflecting excessive stabilisation of behaviour-
al patterns under unphysiological dopaminergic drive of mesocor-
tical regions [19,21]. In order not to miss interactions of DA
supply and task instructions, as have been described for
reinforcement learning [9,13,16,17,23,24], these assumptions were
tested under the opposite demands to selectively execute (Go
version of the task) and to inhibit responses (NoGo version of the
task).
The following main findings were obtained: (i) concerning
reaction time (RT), a uniform increase of response latencies was
observed during deconditioning compared to conditioning; this
effect was not dependent on DA replacement in PD, the disease
itself or the task instruction; (ii) on the level of accuracy, task
performance decreased from conditioning to deconditioning, but
this effect was influenced by the medication state of PD patients
and dependent on the task instruction; (iii), task performance in
patients on levodopa was principally different from that of patients
off levodopa and healthy subjects, the latter groups behaving
similarly.
The expectation that the cancellation of target precueing would
slow down response latencies was confirmed, whereas the
assumption that conditioning itself would - in a process of gradual
learning during rule repetition - decrease RT was not fulfilled,
since no change occurred over the sequential conditioning blocks
in whatever task version. This absence of direct conditioning
effects may be explained by the plainness of demanded responses:
RT for simple button presses may have been saturated ab initio so
that predictive task elements could not further accelerate response
latencies, whereas during deconditioning the violation of the
conditioned expectations led to RT deceleration. The assumption
of primarily saturated response speed appears also compatible with
the observation that RT in PD patients, who disproportionally
slow down under more intricate response demands, did not
significantly diverge from RT in healthy subjects [30–32].
The RT results did not support the hypothesis of a DA role in
non-reinforced learning, since deceleration in deconditioning
occurred uniformly across study participants, i. e., subjects were
affected by the withdrawal of target precueing independently from
their group affiliation.
Concerning performance accuracy, however, specific interac-
tions of levodopa treatment and the task instruction were found.
Principally, error rates differed between conditioning and
deconditioning phases and not between sequential conditioning
blocks, but unlike for the RT results, these differences depended
on whether PD patients were under medication with levodopa or
not. Whereas in patients on levodopa errors increased during
deconditioning in the Go version of the task (as omissions of
required target responses), this was not the case in patients off
levodopa and healthy subjects. Contrarily, in the latter groups
errors increased in the NoGo version of the task (as commission
errors to target stimuli which required response suppression), while
this effect was absent in patients on levodopa.
For interpreting these results, it should also be noted that error
increases during deconditioning were only found after the
presentation of target cues, but not upon non-target stimuli.
Increases of erroneous reactions to non-target stimuli, however,
could have been expected, since precues in the conditioning
Figure 3. Errors in the NoGo version of the task. In the NoGo version of the task, erroneous reactions to target signals were executed responses
(commission errors). The average rate of target commission errors is displayed per group over blocks of 40 presentations over the 120 presentations
during conditioning (blocks 1 to 3, labelled C1, C2 and C3) and the subsequent 40 presentations during deconditioning (block 4, labelled D). The error
bars indicate the standard error of the mean. Note the significant increase of commission errors during deconditioning compared to any of the
conditioning blocks in healthy subjects and patients with Parkinson’s disease off levodopa (indicated by asterisks), whereas in patients on levodopa
this effect could not be detected.
doi:10.1371/journal.pone.0027695.g003
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for the subsequent occurrence of target stimuli. Accordingly,
during deconditioning ‘target responses’ to non-target stimuli (after
former precues) would have indicated maintained adherence to
the expired coupling rule. That this was not the case, but that
levodopa instead changed reaction tendencies to target stimuli
raises the question on which processes the treatment eventually
acted.
In this regard, it is interesting that in implicit, non-reinforced
learning, as studied here, environmental rules are extracted from
repetitive information related to prevailing behaviours [33].
Against this background, the expected representation of precue-
target coupling seems only one possible strategy for the formation
of behaviour. Alternatively, the rules related to stimuli which are
predictive of the habitual, i. e., non-target behaviour might be
targeted by a more global learning approach. In this formulation,
task participants would first of all learn the predictivity of all non-
precues, being seventy five percent of all stimuli, for subsequent
non-target reactions. This would define the increased tendency to
provide ‘non-target reactions’ to target stimuli in deconditioning,
being the only task phase in which non-target stimuli could be
followed by target cues. However, while the strengthening of this
process by PD treatment can be understood within the concept of
DA-dependent stabilisation of behaviour [19,21], it remains to be
settled why levodopa intake should reverse respective effects,
which in controls and in untreated patients have been observed
only in the NoGo task version.
Worthwhile noticing, the overall error rate was several-fold
higher in the NoGo than in the Go version of the task. This
suggests a relation between the particular error increase during
deconditioning and task difficulty in controls and untreated PD
patients. A simple explanation for this could be that perpetuated
response tendencies, leading to erroneous reactions, cannot be
adequately controlled, if high cognitive effort has to be spent on
proper task accomplishment (as in NoGo), whereas the resources
for such control can be mobilised in cognitively less demanding
tasks (as in Go). Concerning the levodopa-mediated reversal of this
effect, interactions of DA supply and task instructions seem to
come into play: high DA levels unfold a negative impact on
reinforced inhibition learning [9,13,16,17,23,24] and, accordingly,
the lack of carry-over errors in the NoGo task version in treated
PD patients could indicate attenuated learning when the demand
was to selectively suppress habitual responses. Contrarily, when
the selective execution of a response was required, high DA levels
in medicated PD patients could have mediated overshooting
stabilisation of the prevalent behaviour, explaining the occurrence
of carry-over errors even in the relatively simple Go version of the
task.
We did not find PD itself to impair habit conditioning as a
consequence of striatal DA depletion [20]. Thus, the overall results
support the idea of disequilibrating still intact DA-dependent
functions by pharmacological replacement therapy in PD [6–9].
Candidate target regions for the present overdose effects are
ventral fronto-striatal and mesocortical dopaminergic networks —
a challenging issue for additional neuroimaging studies.
In conclusion, DA states influenced task performance depend-
ing on the given instruction, but contrary to reinforcement
learning [13–15], high DA levels appear to enhance the most
frequent reaction type rather than selectively demanded responses,
when action feedback is unavailable. This is also of interest from a
Figure 4. Errors in the Go version of the task. In the Go version of the task, erroneous reactions to target signals were response omissions. The
average target omission rate is displayed per group over blocks of 40 presentations over the 120 presentations during conditioning (blocks 1 to 3,
labelled C1, C2 and C3) and the subsequent 40 presentations during deconditioning (block 4, labelled D). The error bars indicate the standard error of
the mean. Note the significant increase of response omissions during deconditioning compared to any of the conditioning blocks in patients with
Parkinson’s disease on levodopa (indicated by asterisks), which was not found in patients in and patients off levodopa and healthy subjects.
doi:10.1371/journal.pone.0027695.g004
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PD is usually associated with the evolution of impulsive-
compulsive behaviour [34–43]. Nevertheless, the present findings
suggest that, if neutral actions are carried out against a
background of inactivity, replacement therapy might also foster
passive behavioural tendencies. As these are commonly considered
disease-inherent rather than drug-induced in PD [44–46],
clinicians should be sensitised not only to what patients under
dopaminergic treatment excessively do, but also to what they
not do.
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